GCM
VRDN icon

Greenland Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Greenland Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
+10,000
New +$161K 0.02% 273

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Greenland Capital Management's VRDN Position: Q2 2026 in Review

Greenland Capital Management reduced its Viridian Therapeutics (VRDN) stake by 9.1% in Q2 2026, selling an estimated $80.6K and leaving 50,000 shares worth $919K. The position accounts for 0.11% of the portfolio, ranked #149.

Greenland Capital Management first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.08M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Greenland Capital Management held 50,000 shares of Viridian Therapeutics worth $919K as of Q2 2026.
  • Greenland Capital Management sold 5,000 Viridian Therapeutics shares in Q2 2026, an estimated $80.6K.
  • Viridian Therapeutics made up 0.11% of Greenland Capital Management's portfolio in Q2 2026, its #149 holding.
  • Greenland Capital Management first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Greenland Capital Management's Viridian Therapeutics position peaked at $1.08M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Greenland Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.